98%
921
2 minutes
20
Purpose: This study aimed to develop predictive models for pathological residual disease after neoadjuvant chemoradiation (CRT) in locally advanced cervical cancer (LACC) by integrating parameters derived from transvaginal ultrasound, MRI and PET/CT imaging at different time points and time intervals.
Methods: Patients with histologically proven LACC, stage IB2-IVA, were prospectively enrolled. For each patient, the three examinations were performed before, 2 and 5 weeks after treatment ("baseline", "early" and "final", respectively). Multivariable logistic regression models to predict complete vs. partial pathological response (pR) were developed and a cost analysis was performed.
Results: Between October 2010 and June 2014, 88 patients were included. Complete or partial pR was found in 45.5% and 54.5% of patients, respectively. The two most clinically useful models in pR prediction were (1) using percentage variation of SUV retrieved at PET/CT "baseline" and "final" examination, and (2) including high DWI signal intensity (SI) plus, ADC, and SUV collected at "final" evaluation (area under the curve (95% Confidence Interval): 0.80 (0.71-0.90) and 0.81 (0.72-0.90), respectively).
Conclusion: The percentage variation in SUV in the time interval before and after completing neoadjuvant CRT, as well as DWI SI plus ADC and SUV obtained after completing neoadjuvant CRT, could be used to predict residual cervical cancer in LACC patients. From a cost point of view, the use of MRI and PET/CT is preferable.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296350 | PMC |
http://dx.doi.org/10.3390/cancers15123071 | DOI Listing |
Int J Gen Med
September 2025
Suzhou Medical College of Soochow University, Suzhou, Jiangsu, People's Republic of China.
Purpose: The fourth most common cause of cancer-related deaths in women is cervical cancer. Though treatment of early-stage cervical cancer is often effective, middle and advanced stage cervical cancer is hard to treat and prone to recurrence. We sought to explore the mechanism underlying cervical cancer progression to identify new therapeutic approaches.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden.
Background: Metabolic reprogramming is an important hallmark of cervical cancer (CC), and extensive studies have provided important information for translational and clinical oncology. Here we sought to determine metabolic association with molecular aberrations, telomere maintenance and outcomes in CC.
Methods: RNA sequencing data from TCGA cohort of CC was analyzed for their metabolic gene expression profile and consensus clustering was then performed to classify tumors into different groups/subtypes.
Front Microbiol
August 2025
Department of Immunology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
The genus is a heterogenous group of commensal and pathogenic bacteria. Members of this genus are classified into two major groups, the pyogenic group and the viridans group streptococci (VGS). VGS are frequently found as normal members of the human microbiome and are regarded as commensals.
View Article and Find Full Text PDFBiochem Biophys Rep
June 2025
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Background: SLC16A3, a highly expressed H + -coupled symporter, facilitates lactate transport via monocarboxylate transporters (MCTs), contributing to acidosis. Although SLC16A3 has been implicated in tumor development, its role in tumor immunity remains unclear.
Methods: A pan-cancer analysis was conducted using datasets from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, and Genotype-Tissue Expression projects.
Surg Case Rep
September 2025
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Toyama, Japan.
Introduction: There are no reports of patients undergoing McKeown esophagectomy for esophageal cancer after undergoing pancreaticoduodenectomy for pancreatic cancer. We report the case of a patient who underwent subtotal esophagectomy and colon reconstruction after pancreaticoduodenectomy using the mesenteric approach.
Case Presentation: A 71-year-old male was diagnosed with advanced esophageal cancer.